EMERGING RESEARCHER APPOINTED TO JAMES PACKER CHAIR IN MOOD DISORDERS AT UNSW Joins department with over 60 years research in Psychiatry and Mental Health to investigate Bipolar Disorder
The UNSW Discipline of Psychiatry and Mental Health is widely renowned as the pre-eminent psychiatry research department in the country and one of the leading university psychiatry research groups internationally. In 2023 it celebrated 60 Years of Psychiatry & Mental Health at UNSW Sydney.
Australian Health Journal spoke with Professor Kimberlie Dean, Head of the Discipline of Psychiatry and Mental Health at UNSW Sydney, about the recent appointment of mental health disorders expert and clinician researcher Dr Aswin Ratheesh to lead the James Packer Chair in Mood Disorders at UNSW Sydney.
Professor Dean spoke about UNSW being home to an outstanding mental health research community with key partners across the Mindgardens Neuroscience Network, welcoming Dr Ratheesh
As a leading clinical researcher in mood and psychotic disorders, Dr Ratheesh is passionate about prompt and early access to interventions for people with such conditions.
The appointment comes after prominent businessman and investor James Packer, jointly with The Packer Family Foundation, made a $7 million gift to establish the role last year.
The Chair will lead a new unit at UNSW and the Mindgardens Neuroscience Network that will conduct rigorous research in mental health, with a particular focus on mood disorders such as bipolar disease. The gift also funds a team of researchers to support the Chair.
Dr Ratheesh’s research is focused on understanding pathways leading to the onset of mood disorders and finding ways to provide effective treatments for individuals who develop such conditions. He has worked as a psychiatrist for over 12 years both in youth and adult mental health settings and has led several studies that have helped identify risk markers for future bipolar disorder.
He believes some of the current knowledge gaps in mood disorders include our ability to predict who will develop such conditions, who is at risk of worsening, and who will respond to specific treatments.
Dr Ratheesh currently leads an NHMRC Partnership grant in early intervention for bipolar disorder and is a chief investigator on a Centre of Research Excellence grant in early intervention for bipolar disorder. He co-leads the International Society of Bipolar Disorders Taskforce on Early Intervention and is an Associate Editor for the leading journal, the Australian and New Zealand Journal of Psychiatry. He has received awards from the International Early Psychosis Association and the Australasian Society for Bipolar and Depressive Disorders for his research.
-
Professor Jeffrey Braithwaite on patient safety and health systems improvement
Professor Jeffrey Braithwaite is Founding Director of the Australian Institute of Health Innovation, Director of the Centre for Healthcare Resilience and Implementation Science and Professor of Health Systems Research at Macquarie University.
Professor Jeffrey Braithwaite is a leading health services and systems researcher with an international reputation for his work investigating and contributing to systems improvement.
The Australian Healthcare and Hospitals Association (AHHA) recently announced it will award the 2021 Sidney Sax medal for outstanding contributions to the development and improvement of Australia’s healthcare system to Professor Jeffrey Braithwaite.
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
-
Role of milk in cognitive function and quality of life in older adults
New research emphasises the role of cows’ milk, particularly A1 protein free milk, in enhancing cognitive function and quality of life for older adults with mild cognitive impairment (MCI). A multi-centre, double-blinded, randomised controlled clinical study published in *The Journal of Nutrition, Health and Aging* evaluated 88 milk-tolerant Chinese adults aged 65-75 over three months. Participants consumed either ordinary skim milk or A1 protein free skim milk, leading to improvements in various cognitive assessments.
